BACKGROUND: The current study was conducted to determine whether amifostine is effective in reducing the toxicities associated with the administration of platinum-containing regimens in children with hepatoblastoma (HB). METHODS:Patients were enrolled on P9645 beginning in March of 1999. Patients who had stage I/II disease received treatment with 4 cycles of combined cisplatin, 5-fluorouracil, and vincristine (C5V) with or without amifostine. Patients who had stage III/IV disease were randomized to receive treatment with 6 cycles of either C5V with or without amifostine or carboplatin alternating with cisplatin (CC) with or without amifostine. Patients who were randomized to receive amifostine were given a dose of 740 mg/m2 intravenously over 15 minutes before each administration of a platinum agent. RESULTS: Eighty-two patients were considered in a special interim analysis of the incidence of toxicity. The disease outcome for patients who received amifostine was similar to the outcome for patients who did not receive amifostine (P=.22). The incidence of significant hearing loss (>40 dB) was similar for patients who did or did not receive amifostine (38% [14 of 37 patients] vs 38% [17 of 45 patients], respectively; P=.68). There were no differences in the incidence of renal or bone marrow toxicities evaluated. Patients who received amifostine had a higher incidence of hypocalcemia (5% vs 0.5%; P=.00006). CONCLUSIONS:Amifostine in the doses and schedule used in this study failed to significantly reduce the incidence of platinum-induced toxicities in patients with HB. Copyright (c) 2009 American Cancer Society.
RCT Entities:
BACKGROUND: The current study was conducted to determine whether amifostine is effective in reducing the toxicities associated with the administration of platinum-containing regimens in children with hepatoblastoma (HB). METHODS:Patients were enrolled on P9645 beginning in March of 1999. Patients who had stage I/II disease received treatment with 4 cycles of combined cisplatin, 5-fluorouracil, and vincristine (C5V) with or without amifostine. Patients who had stage III/IV disease were randomized to receive treatment with 6 cycles of either C5V with or without amifostine or carboplatin alternating with cisplatin (CC) with or without amifostine. Patients who were randomized to receive amifostine were given a dose of 740 mg/m2 intravenously over 15 minutes before each administration of a platinum agent. RESULTS: Eighty-two patients were considered in a special interim analysis of the incidence of toxicity. The disease outcome for patients who received amifostine was similar to the outcome for patients who did not receive amifostine (P=.22). The incidence of significant hearing loss (>40 dB) was similar for patients who did or did not receive amifostine (38% [14 of 37 patients] vs 38% [17 of 45 patients], respectively; P=.68). There were no differences in the incidence of renal or bone marrow toxicities evaluated. Patients who received amifostine had a higher incidence of hypocalcemia (5% vs 0.5%; P=.00006). CONCLUSIONS:Amifostine in the doses and schedule used in this study failed to significantly reduce the incidence of platinum-induced toxicities in patients with HB. Copyright (c) 2009 American Cancer Society.
Authors: J A Ortega; M D Krailo; J E Haas; D R King; A R Ablin; J J Quinn; J Feusner; J R Campbell; D A Lloyd; J Cherlow Journal: J Clin Oncol Date: 1991-12 Impact factor: 44.544
Authors: Marcio H Malogolowkin; Howard Katzenstein; Mark D Krailo; Zhengjia Chen; Laura Bowman; Marleta Reynolds; Milton Finegold; Brian Greffe; Jon Rowland; Kurt Newman; Richard B Womer; Wendy B London; Robert P Castleberry Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: S Wadler; J J Beitler; J S Rubin; H Haynes; F McGill; A Rozenblit; G Goldberg; C Cohen; J Speyer; C Runowicz Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: G Kemp; P Rose; J Lurain; M Berman; A Manetta; B Roullet; H Homesley; D Belpomme; J Glick Journal: J Clin Oncol Date: 1996-07 Impact factor: 44.544
Authors: Alexander J Towbin; Rebecka L Meyers; Helen Woodley; Osamu Miyazaki; Christopher B Weldon; Bruce Morland; Eiso Hiyama; Piotr Czauderna; Derek J Roebuck; Greg M Tiao Journal: Pediatr Radiol Date: 2018-02-09
Authors: Wendy Landier; Kristin Knight; F Lennie Wong; Jin Lee; Ola Thomas; Heeyoung Kim; Susan G Kreissman; Mary Lou Schmidt; Lu Chen; Wendy B London; James G Gurney; Smita Bhatia Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: James G Gurney; Johnnie K Bass; Arzu Onar-Thomas; Jie Huang; Murali Chintagumpala; Eric Bouffet; Tim Hassall; Sridharan Gururangan; John A Heath; Stewart Kellie; Richard Cohn; Michael J Fisher; Atmaram Pai Panandiker; Thomas E Merchant; Ashok Srinivasan; Cynthia Wetmore; Ibrahim Qaddoumi; Clinton F Stewart; Gregory T Armstrong; Alberto Broniscer; Amar Gajjar Journal: Neuro Oncol Date: 2014-01-10 Impact factor: 12.300
Authors: Kristin R Knight; Lu Chen; David Freyer; Richard Aplenc; Mary Bancroft; Bonnie Bliss; Ha Dang; Biljana Gillmeister; Eleanor Hendershot; Dale F Kraemer; Lanie Lindenfeld; Jane Meza; Edward A Neuwelt; Brad H Pollock; Lillian Sung Journal: J Clin Oncol Date: 2016-12-12 Impact factor: 44.544